Product and Clinical Stage Pipeline

Sage Pipeline

*Under a collaboration agreement between Sage and Shionogi & Co., Ltd., Shionogi has the right to develop and commercialize zuranolone in Japan, Taiwan, and South Korea.
**Biogen terminated its rights as to the SAGE-324 program in September 2024; the termination will be effective on February 17, 2025.

Please refer to the U.S. Prescribing Information for ZURZUVAE
Safety and efficacy for investigational uses or compounds have not been established. There is no guarantee that the outcome of these studies will be positive or result inapproval by a health authority.